Article Text

PDF
The RCPCH care pathway for children with latex allergies: an evidence- and consensus-based national approach
  1. Jane S Lucas1,
  2. George du Toit2,
  3. Kate Lloyd3,
  4. Louise Sinnott4,
  5. Debra Forster5,
  6. Moira Austin6,
  7. Christine Clark7,
  8. David Tuthill8,
  9. Nicola Brathwaite9,
  10. John Warner10 on behalf of the Science and Research Department, Royal College of Paediatrics and Child Health
  1. 1Division of Infection Inflammation and Immunity, Faculty of Medicine, University of Southampton, Southampton, UK
  2. 2Department of Paediatric Allergy, Guy's and St Thomas' NHS Foundation Trust, London, UK
  3. 3Department of Science and Research, Royal College of Paediatrics and Child Health, London, UK
  4. 4North West Specialised Commissioning Team, Warrington, UK
  5. 5Children's Clinic (South), RCN Nurses Allergy Group, Nottingham, UK
  6. 6Anaphylaxis Campaign, Farnborough, UK
  7. 7Independent consultant pharmacist and medical writer, London, UK
  8. 8Department of Paediatrics, Children's Hospital for Wales, Cardiff, UK
  9. 9Department of Paediatric Allergy, Kings College Hospital NHS Foundation Trust, London, UK
  10. 10Department of Paediatrics, Imperial College, London, UK
  1. Correspondence to Dr Jane Lucas, Division of Infection Inflammation and Immunity (MP 803), University of Southampton, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK; jlucas1{at}soton.ac.uk

Abstract

Aims The Royal College of Paediatrics and Child Health (RCPCH) Science and Research Department was commissioned by the Department of Health to develop national care pathways for children with allergies; the latex allergy pathway is the seventh pathway. The pathways focus on defining the competences to improve the equity of care received by children with allergic conditions.

Method The RCPCH latex allergy pathway was developed by a multidisciplinary working group and was based on a comprehensive review of evidence. The pathway was reviewed by a broad group of stakeholders including the public and approved by the Allergy Care Pathways Project Board and the RCPCH Clinical Standards Committee.

Results The results are presented in four parts, the evidence review, pathway mapping, external review and core knowledge documents. The evidence review highlighted the paucity of recent evidence for latex allergy in childhood. The review found that the diagnostic sensitivity of different latex extracts for skin-prick testing may differ. It also noted that health professionals should be aware of latex allergy, and care should be taken to avoid contact with latex in young infants, especially when there is a family history for latex allergy. The pathway entry points are defined by the severity at presentation.

Conclusions The latex allergy pathway provides a guide for training and development of services to facilitate improvements in delivery as close to the patients home as possible. The authors recommend that this pathway is implemented locally by a multidisciplinary team with a focus on creating networks between primary, secondary and tertiary care to improve services for children with allergic conditions.

Statistics from Altmetric.com

Footnotes

  • Funding This project was funded by the Department of Health.

  • Competing interests GdT: Allergy Therapeutics and Nutrition SHS; DT: Nutricia, SMA; CC: Stiefel, Galderma, Almirall. Leo, Galderma; JL: ALK; JW: Novartis, Danone, Airsonette, Merck, Allergy Therapeutics, Phadia. Research, GSK, AstraZeneca, Merck, Allergy Therapeutics, ALK.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Copyright licence statement The pathways and associated competences remain the copyright of the Royal College of Paediatrics and Child Health.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.